Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115155 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Weiqi Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Cent…. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Graft Rejection, Heart Transplantation, Quinazolinones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Berlin Institute of Health, Tianjin Municipal Natural Science Foundation.
Abstract (Originalsprache)
BACKGROUND: Immune rejection remains a leading cause of graft loss following organ transplantation, with CD4+ T cells playing a central role in this process. The PI3K/AKT/mTOR signaling pathway is essential for the activation, proliferation, and metabolic reprogramming of CD4+ T cells, making it an attractive therapeutic target. However, the role of Idelalisib (ID), a selective PI3Kδ inhibitor, in transplant immunity remains underexplored. METHODS: Purified CD4+ T cells from the spleens of C57BL/6 mice were cultured with ID. Activation, proliferation, differentiation and survival were evaluated. A fully mismatched skin and heart transplantation model was used to assess ID's effects on rejection. Histopathology analysis and transcriptomic sequencing were performed. RESULTS: ID significantly suppressed CD4+ T cell activation, proliferation, and Th1 differentiation, while enhancing cell survival-contrasting with the pro-apoptotic effects observed with the mTOR inhibitor rapamycin (Rapa). In the skin and heart transplantation models, ID reduced acute rejection, extended graft survival, and decreased the proliferation of CD4+ T cells and B cells. Transcriptomic analysis revealed downregulation of genes involved in T cells activation and differentiation (e.g., Zap70, Stat4), as well as markers of glycolysis (e.g., Gapdh, Pfkm). Functional assays confirmed reduced glucose uptake and lactate production in ID-treated cells. CONCLUSIONS: ID uniquely modulates T cell responses through PI3Kδ inhibition, providing a distinct immunosuppressive mechanism from that of mTOR inhibitors. These findings highlight the therapeutic potential of ID in preventing transplant rejection and reveal a critical link between PI3K signaling and CD4+ T cell metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China.
- Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China; Tianjin Medical University First Central Clinical College, Tianjin, China.
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany; Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Ch…
- Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China.
- Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China. Electronic address: nianyeqi0314@hotmail…
- Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China. Electronic address: zhongyangshen@nankai…
Förderung
- National Natural Science Foundation of China
- Berlin Institute of Health
- Tianjin Municipal Natural Science Foundation
Zitieren
APA
Zhang, W., Zhang, X., Hu, L., Jin, S., Pitts, L., Kofler, M., Wang, Z., Iske, J., Nian, Y., & Shen, Z. (2025). Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115155
Vancouver
Zhang W, Zhang X, Hu L, Jin S, Pitts L, Kofler M, et al. Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115155
BibTeX
@article{Zhang2025,
author = {Zhang, Weiqi and Zhang, Xiaohan and Hu, Lu and Jin, Shuai and Pitts, Leonard and Kofler, Markus and Wang, Zhihong and Iske, Jasper and Nian, Yeqi and Shen, Zhongyang},
title = {Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115155}
}
EUVIMED